semaglutide shortage update Hims & Hers stock falls 25% as FDA curtails compounded GLP-1s Drug shortages in 2024 reach

This rise reflects heightened awareness of the drugs potential risks and more patients coming forward with claims

29 The first senolytic agent is the D + Q combination, 29 and the combination therapy of D + Q has been used in multiple aging-related studies in the clinical stage

[1] The clinical trials that led to Ozempic's approval did not identify respiratory symptoms as a significant concern directly attributable to semaglutide therapy

Keep our heart healthy

ABSTRACT: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and dual glucose-dependent insulinotropic polypeptide/GLP-1 RAs are common therapies for managing diabetes and obesity, but gastrointestinal (GI) adverse effects (AEs) such as nausea, vomiting, diarrhea, and constipation frequently limit therapy

Weve got lots of news this morning, so lets get straight into it